fundraisingAllogenetics adds €3.8M for rejection-resistant donor lungsHanover-based Allogenetics has raised €3.8 million in a Pre-Series A round to advance ALG-115, an ex vivo gene therapy for donor lungs, through IND-enabling studies and toward a first-in-human trial … more ➔
StrategySimris steps on Heidelberg Pharma’s toes with amanitin pivotSimris Group is making amanitin-based ADCs the center of its strategy under former Heidelberg Pharma CEO Andreas Pahl — less than two months after hiring the executive who helped build Heidelberg Pharma’s … more ➔
EthrisInfectious diseaseEIB backs Ethris with €30 million for broad-spectrum antiviral mRNAThe European Investment Bank (EIB) is providing German Ethris with €30 million to advance clinical development of its mRNA-based antiviral candidate ETH47. The Munich-based RNA specialist has been … more ➔
CDMONorthway opens €61M Vilnius plant built for personalized medicineCDMO company Northway Biotech has opened a €61 million cell therapy and personalized medicine center in Vilnius that is being qualified for GMP manufacturing, and the company says it expects a manufacturing … more ➔
startupsConnecta raises €3.1M for Fragile X syndrome Phase 2The Barcelona-based biotech will use the financing to complete a 30-patient Phase 2a study of its lead candidate CTH120, with the first efficacy data expected in mid-2027. more ➔
clinical dataTeitur Trophics reports positive phase 1 data for Parkinson’s peptideDanish biotech Teitur Trophics completed its phase 1 study and said its experimental Parkinson’s disease treatment TT-P34 was safe and reached the central nervous system, supporting plans to move the … more ➔
M&ALeyden Labs reveals RIGImmune acquisition with Phase 1 dataDutch biotech Leyden Labs has reported positive Phase 1 results for intranasal RIG-101 and disclosed that it acquired the drug’s developer, RIGImmune, earlier this year. more ➔
Drug deliveryInside exosomes: Nature’s drug carriersNext-gen, effective payloads – from AI-designed small molecules to RNA-based therapeutics and gene therapies – have revolutionized medicine. Yet, the main hurdle remains targeted delivery: avoiding … more ➔
clinical dataPharvaris oral HAE drug cuts attacks by 83% in Phase 3Switzerland-based Pharvaris’ once-daily oral deucrictibant XR reduced hereditary angioedema (HAE) attacks by 83% versus placebo in a pivotal Phase 3 trial, putting the experimental prophylactic into … more ➔
clinical dataNovartis’ $12B Avidity bet suffers Phase 3 blowNovartis has suffered another pipeline setback after del-desiran, an antibody-oligonucleotide conjugate acquired with Avidity Biosciences, failed to significantly improve hand function over placebo in … more ➔
Ethris
